Medilines Distributors, Inc., one of the country’s leading high-value medical equipment distributors, aims to expand its dialysis consumables business which is expected to grow by 43 percent this year.

In a statement, the firm said its dialysis consumables product line alone recorded revenues of P197 million for the full year ending December 31, 2021.

“Medilines commits itself to its growth strategy by fast-tracking its expansion into the dialysis consumables market, a move that will not only accelerate its revenues but also generate higher margins,” it said.

A study by Ken Research in 2021 stated that the size of the domestic dialysis market is expected to grow to Php13.5 billion by 2023, with bulk of this market accounted for by the dialysis consumables segment.

Dialysis consumables include dialyzers, concentrate solution, and bloodlines, among others.

According to the same study, Medilines captured 50.5 percent market share in terms of revenues of all dialysis products sold by distributors in the Philippines as of 2021.

“There is a significant opportunity to service the dialysis market in the Philippines, and Medilines is moving quickly to be a leader not just on the equipment side, but also in the much larger consumables side of the market,” said Medilines Chairman Virgilio B. Villar.

He noted that, “This will be a significant driver of our company’s growth moving forward. More importantly, this is well in line with our mission to make quality healthcare more accessible to Filipinos.”

On the back of management’s view of Medilines’ strong fundamentals and growth prospects, the Company announced yesterday a share buyback program of up to P100 million.

“Amidst market volatility, we remain confident in the long-term value of our company and the many opportunities available to us in the healthcare industry,” said Medilines President and CEO Patricia V. Yambing.

She added that, “We are very focused on business strategies that will deliver profitable and sustainable growth over time.”

“In addition, we are working to enhance shareholder value through regular dividends declaration, the recently announced share buyback program, and other investor relations initiatives,” said Yambing.

Since its listing on the Philippine Stock Exchange in December last year, Medilines has declared and paid two cash dividends totaling P25 million, equivalent to 15 percent of the Company’s 2021 net income.